CD47 and follicular lymphoma: Hu5F9-G4 (hereafter, 5F9), an anti-CD47 humanized IgG4 antibody that binds to monomeric human CD47, is currently being assessed in four different phase I trials and has received fast-track designation by the US Food and Drug Administration for further development for the treatment of DLBCL and follicular lymphoma (FL).